Advertisement
The session will begin at 4 p.m. in room 30A of the San Diego ConventionCenter.
As previously announced, Iomai and Intercell AG have entered into anagreement whereby Iomai has agreed to be acquired by Intercell AG.
Advertisement
About Iomai Cooperation
Iomai Corporation discovers and develops vaccines and immune systemstimulants, delivered via a novel, needle-free technology calledtranscutaneous immunization (TCI). TCI, discovered by researchers at theWalter Reed Army Institute of Research, taps into the unique benefits of amajor group of antigen-presenting cells found in the outer layers of the skin(Langerhans cells) to generate an enhanced immune response. Iomai isleveraging TCI to enhance the efficacy of existing vaccines, develop newvaccines that are viable only through transcutaneous administration and expandthe global vaccine market. Iomai currently has four product candidates indevelopment: three targeting influenza and pandemic flu and one to preventtravelers' diarrhea. For more information on Iomai, please visithttp://www.iomai.com.
Iomai announced on May 12 that it has entered into an agreement withIntercell AG in which Intercell will acquire Iomai for $6.60 a share.
About Intercell AG
Intercell AG is a growing biotechnology company which focuses on thedesign and development of novel vaccines for the prevention and treatment ofinfectious diseases with substantial unmet medical need. The Company developsantigens and adjuvants which are derived from its proprietary technologyplatforms and has in-house GMP manufacturing capabilities. Based on thesetechnologies, Intercell has strategic partnerships with a number of globalpharmaceutical companies, including Novartis, Merck & Co., Inc., Wyeth, SanofiPasteur, Kirin, and the Statens Serum Institut.
The Company's leading product, a prophylactic vaccine against JapaneseEncephalitis, successfully concluded pivotal Phase III clinical trials in2006. The Market Authorization Application (MAA) in Europe as well as theBiological License Application (BLA) with the US Food and Drug Administration(FDA) for the use of the vaccine to prevent Japanese Encephalitis weresubmitted in December of 2007. The licensure application to TGA (TherapeuticGoods Administration) in Australia was submitted in February of 2008.
The Company's broad development pipeline includes a partnered S. aureusvaccine in Phase II, a therapeutic vaccine against Hepatitis C in Phase II, aPseudomonas vaccine in Phase II, a partnered Tuberculosis vaccine (Phase
I/II), and five products focused on infectious diseases in preclinicaldevelopment.
Intercell is listed on the Prime Market of the Vienna Stock Exchange underthe symbol "ICLL".
ISIN: AT0000612601
For more information on Intercell, please visit: http://www.intercell.com
SOURCE Iomai Corporation
